Sangamo Therapeutics Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sangamo Biosciences (SGMO) Reports Q2 Loss of $0.17/Share
August 9, 2017 4:08 PM EDTSangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.17), versus ($0.38) reported last year. Revenue for the quarter came in at $8.3 million, versus $3.7 million reported last year.
GUIDANCE:
Sangamo Biosciences sees FY2017 revenue of $30-40 million, versus the consensus of $31.2 million.
For... More
